126 related articles for article (PubMed ID: 35772614)
21. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure.
Wang J; Susam MM; Gan C; Sparidans RW; Lebre MC; Beijnen JH; Schinkel AH
Pharmaceuticals (Basel); 2022 Sep; 15(9):. PubMed ID: 36145346
[TBL] [Abstract][Full Text] [Related]
22. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.
Wang J; Gan C; Sparidans RW; Wagenaar E; van Hoppe S; Beijnen JH; Schinkel AH
Pharmacol Res; 2018 Mar; 129():414-423. PubMed ID: 29155017
[TBL] [Abstract][Full Text] [Related]
23. Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib.
Wang Y; Sparidans RW; Wang J; Li W; Lebre MC; Beijnen JH; Schinkel AH
Eur J Pharm Biopharm; 2022 Jan; 170():197-207. PubMed ID: 34952136
[TBL] [Abstract][Full Text] [Related]
24. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
[TBL] [Abstract][Full Text] [Related]
25. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice.
Tang SC; Sparidans RW; Cheung KL; Fukami T; Durmus S; Wagenaar E; Yokoi T; van Vlijmen BJ; Beijnen JH; Schinkel AH
Clin Cancer Res; 2014 Jun; 20(12):3133-45. PubMed ID: 24727322
[TBL] [Abstract][Full Text] [Related]
26. P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice.
Tang SC; Kort A; Cheung KL; Rosing H; Fukami T; Durmus S; Wagenaar E; Hendrikx JJ; Nakajima M; van Vlijmen BJ; Beijnen JH; Schinkel AH
Mol Pharm; 2015 Oct; 12(10):3714-23. PubMed ID: 26317243
[TBL] [Abstract][Full Text] [Related]
27. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
van Waterschoot RA; ter Heine R; Wagenaar E; van der Kruijssen CM; Rooswinkel RW; Huitema AD; Beijnen JH; Schinkel AH
Br J Pharmacol; 2010 Jul; 160(5):1224-33. PubMed ID: 20590614
[TBL] [Abstract][Full Text] [Related]
28. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847
[TBL] [Abstract][Full Text] [Related]
29. Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites.
F Martins ML; Heydari P; Li W; Martínez-Chávez A; Venekamp N; Lebre MC; Lucas L; Beijnen JH; Schinkel AH
Front Pharmacol; 2022; 13():855000. PubMed ID: 35308219
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
Durmus S; Sparidans RW; van Esch A; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512
[TBL] [Abstract][Full Text] [Related]
31. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Eur J Pharm Biopharm; 2019 Mar; 136():120-130. PubMed ID: 30660696
[TBL] [Abstract][Full Text] [Related]
32. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
Poller B; Iusuf D; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2011 May; 39(5):729-35. PubMed ID: 21282407
[TBL] [Abstract][Full Text] [Related]
33. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
[TBL] [Abstract][Full Text] [Related]
34. In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters.
Durmus S; Naik J; Buil L; Wagenaar E; van Tellingen O; Schinkel AH
Int J Cancer; 2014 Oct; 135(7):1700-10. PubMed ID: 24554572
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.
van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2017 Jun; 120():43-50. PubMed ID: 28288939
[TBL] [Abstract][Full Text] [Related]
36. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725
[TBL] [Abstract][Full Text] [Related]
37. Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.
Higgins JW; Bao JQ; Ke AB; Manro JR; Fallon JK; Smith PC; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2014 Jan; 42(1):182-92. PubMed ID: 24194513
[TBL] [Abstract][Full Text] [Related]
38. Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance.
Lee HH; Leake BF; Kim RB; Ho RH
Mol Pharmacol; 2017 Jan; 91(1):14-24. PubMed ID: 27777271
[TBL] [Abstract][Full Text] [Related]
39. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
[TBL] [Abstract][Full Text] [Related]
40. Role of the efflux transporters Abcb1 and Abcg2 in the brain distribution of olaparib in mice.
Song YK; Kim MJ; Kim MS; Lee JH; Chung SJ; Song JS; Chae YJ; Lee KR
Eur J Pharm Sci; 2022 Jun; 173():106177. PubMed ID: 35341895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]